Ariad Pharmaceuticals, Inc.

• What’s Moving These Biotech Stocks?

  By Brian Nichols - May 18, 2013 | Tickers: ARIA, INFI, ONTY

  As one of the most important conferences in biotechnology approaches (ASCO) we are seeing wild swings of volatility. On Thursday there were several stocks that moved to the downside, and in this piece I am determining if any are a buy after the large moves.

  Ariad Pharmaceuticals (NASDAQ: ARIA)

  Shares of Ariad Pharmaceuticals fell more than 4% after a report from Fox News suggested that cancer patients are now electing more »

• These 3 Biotech Stocks Look Interesting

  By Shas Dey - April 30, 2013 | Tickers: ARIA, ARRY, CLDX

  Three biotech companies are making themselves heard in the stock market. They are making a mark in the life sciences space with their unique mix of science and strategy.

  Ariad Pharmaceuticals (NASDAQ: ARIA) is on the focused approach trajectory, using its solid foundation in the sciences to fill the holes left open by big pharma. Celldex Therapeutics (NASDAQ: CLDX) is exercising first-mover advantage by developing a novel but potent approach more »

• Under-the-Radar Hedge Fund Focusing on Pharma

  By Meena Krishnamsetty - March 20, 2013 | Tickers: ARIA, PODD, PCYC, YMI.DL

  Hedge funds are typically thought of as being billion dollar funds managed by Harvard MBAs and alums of some of Wall Street’s more prestigious analyst programs (i.e. Goldman Sachs, JP Morgan). Interestingly, Dafna Capital Management is rather small (only $63 million) and is managed by Dr. Nathan Fischel MD and his wife, a biomedical engineer. So why are we even talking about Dafna? Because according to the most more »

• Billionaire Dan Loeb, Third Point Making Moves Last Quarter

  By Meena Krishnamsetty - February 18, 2013 | Tickers: ABT, ABBV, AAPL, ARIA, EA

  In the hedge fund universe, 13F filing season is here, and we’re bringing you up-to-date coverage of this situation. Our research has shown that hedgies’ consensus small-cap stock picks beat the market by 18 percentage points per year (use our market-beating strategy). Last year the most popular large cap stocks among billionaire fund managers outperformed the S&P 500 index by 8 percentage points as well. Dan Loeb is more »

• Five Amazing Biotech Picks with Futuristic Technology

  By Streetwise Reports - January 29, 2013 | Tickers: ARIA, ASTX, GALE, SRPT

  Michael King is looking for the monoclonal antibodies of tomorrow. When I first spoke to him 15 or more years ago, King was talking up Immunex, which would later be taken out by Amgen for $16 billion for its anti-tumor necrosis factor (anti-TNF) fusion protein Enbrel (etanercept) to treat rheumatoid arthritis. Today Amgen’s (via Immunex) Enbrel and the anti-TNF monoclonal antibodies that would follow-- Johnson & Johnson’s Remicade (infliximab more »

• Billionaire Steve Cohen’s Most Promising Stock Picks

  By Meena Krishnamsetty - January 12, 2013 | Tickers: ARIA, ENDP, NCR, SPN, VC

  Small-cap and mid-cap stocks don’t get as much attention from bankers, third-party analysts, and the media, which often leaves them less efficiently priced than large- and mega-caps. Hedge funds sometimes take advantage of this by dedicating their research teams to work on these lower valuation stocks as well, and so often earn substantial alpha from their investments. Retail investors can use smaller-cap stocks that hedge funds reported owning as more »

• Big Wave Trading Portfolio Update And Top Current Holdings

  By Joshua Hayes - December 14, 2012 | Tickers: ASPS, AMCC, ARIA, BBRY, CNC, FB, FSLR, GOOG, GMCR, PCLN, QCOM, SWHC

  The Big Wave Trading portfolio remains under a NEUTRAL signal. However, we did switch to a BUY signal for 2 days before switching back to NEUTRAL. Fortunately for us, we have already closed shop on our model for the year. After the final and barely successful SELL signal it was decided that with the current price/volume pattern in the overall market, the upcoming Fiscal Cliff drama, and the news more »

• Can These Biotechs Make You Money In 2012?

  By Robert Fisher - January 14, 2012 | Tickers: ARIA, DNDN, HGSI, ILMN, MNKD

  The biotech group is among the largest in the market in terms of the number of companies. They trade with perhaps the highest volatility in the market and move heavily on optimism of future successful drugs. The five biotech stocks on my radar today are Dendreon Corp. (NASDAQ: DNDN), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Human Genome Sciences (NASDAQ: HGSI), Illumina Inc. (NASDAQ: ILMN) and MannKind Corp. (NASDAQ: MNKD). The outlook more »